Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]-
Malignant Pleural Mesothelioma
Explore 35 assets in Malignant Pleural Mesothelioma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Ikena Oncology
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05228015CT.gov Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pleural Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- (this asset) | Ikena Oncology | P1 | CC · 43 |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P2 | BB |
| Carboplatin | AstraZeneca | P2 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P2 | B |
| Pembrolizumab | NuCana plc | P2 | B |
| Atezolizumab | Swiss Cancer Institute | P2 | B |
| Decitabine | National Cancer Institute (NCI) | P1/2 | CCC |
| Regorafenib | Translational Research in Oncology | P2 | CCC |
| Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific | M.D. Anderson Cancer Center | P2 | CCC |
+42 more in the Malignant Pleural Mesothelioma cohort
Other indications for Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epithelioid Hemangioendothelioma | — | P1 | CC · 43 |
| Mesothelioma | — | P1 | CC · 43 |
| NF2-Related Schwannomatosis | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- in Malignant Pleural Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/benzenesulfonamide-n-methyl-3-1-methyl-1h-imidazol-4-yl-4-4-trifluoromethylphenylmethylamino-malignant-pleural-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →